Immunopathogenesis of immune reconstitution disease in HIV patients responding to antiretroviral therapy

Current Opinion in HIV and AIDS

Volumn 3, Issue 4, 2008, Pages 419-424

  Kestens, Luc ^a   Seddiki, Nabila ^b   Bohjanen, Paul R ^c  

^a INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Antiretroviral treatment; HIV AIDS; Immune reconstitution; Immunopathogenesis; IRD; IRIS

Indexed keywords

LEUKOTRIENE; MONTELUKAST;

ANTIVIRAL THERAPY; CELL FUNCTION; CRYPTOCOCCUS; DISEASE ASSOCIATION; EFFECTOR CELL; GENETIC PREDISPOSITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; MACROPHAGE; MYCOBACTERIUM TUBERCULOSIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SCHISTOSOMIASIS; TREATMENT RESPONSE; VIRUS INFECTION;

EID: 54849425795     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328302ebbb     Document Type: Review

References (62)

1. French MA. Disorders of immune reconstitution in patients with HIV infection responding to antiretroviral therapy. Curr HIV/AIDS Rep 2007; 4:16-21.
2. Lawn SD, French M. Immune reconstitution disease: recent developments and implications for antiretroviral treatment in resource-limited settings. Current Opinion in HIV & AIDS 2007; 2:339-345.
3. Dhasmana DJ, Dheda K, Ravn P, et al. Immune reconstitution inflammatory syndrome in HIV-infected patients receiving antiretroviral therapy: pathogenesis, clinical manifestations and management. Drugs 2008; 68:191-208. This is an excellent general overview of the various aspects of IRD.
4. Murdoch DM, Venter WD, Van RA, Feldman C. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007; 4:9.
5. French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active anti-retroviral therapy. HIV Med 2000; 1:107-115.
6. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ. Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006; 42:418-427.
7. Munier ML, Kelleher AD. Acutely dysregulated, chronically disabled by the enemy within: T-cell responses to HIV-1 infection. Immunol Cell Biol 2007; 85:6-15.
8. Stone SF, Price P, Keane NM, et al. Levels of IL-6 and soluble IL-6 receptor are increased in HIV patients with a history of immune restoration disease after HAART. HIV Med 2002; 3:21-27.
9. Keane NM, Price P, Lee S, et al. An evaluation of serum soluble CD30 levels and serum CD26 (DPPIV) enzyme activity as markers of type 2 and type 1 cytokines in HIV patients receiving highly active antiretroviral therapy. Clin Exp Immunol 2001; 126:111-116.
10. Sadeghi M, Susal C, Daniel V, et al. Short communication: decreasing soluble CD30 and increasing IFN-gamma plasma levels are indicators of effective highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2007; 23:886-890.
11. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20:F1-F7.
12. Price P, Keane NM, Stone SF, et al. MHC haplotypes affect the expression of opportunistic infections in HIV patients. Hum Immunol 2001; 62:157-164.
13. Price P, Morahan G, Huang D, et al. Polymorphisms in cytokine genes define subpopulations of HIV-1 patients who experienced immune restoration diseases. AIDS 2002; 16:2043-2047.
14. Schrier RD, Song MK, Smith IL, et al. Intraocular viral and immune pathogenesis of immune recovery uveitis in patients with healed cytomegalovirus retinitis. Retina 2006; 26:165-169.
15. Ruhwald M, Ravn P. Immune reconstitution syndrome in tuberculosis and HIV-co-infected patients: Th1 explosion or cytokine storm? AIDS 2007; 21: 882-884.
16. Saunders BM, Frank AA, Orme IM, Cooper AM. CD4 is required for the development of a protective granulomatous response to pulmonary tuberculosis. Cell Immunol 2002; 216:65-72.
17. Stone SF, Price P, French MA. Immune restoration disease: a consequence of dysregulated immune responses after HAART. Curr HIV Res 2004; 2:235-242.
18. French MA. The immunopathogenesis of mycobacterial immune restoration disease. Lancet Infect Dis 2006; 6:461-462.
19. Van den BR, Vanham G, Raes G, et al. Mycobacterium-associated immune reconstitution disease: macrophages running wild? Lancet Infect Dis 2006; 6:2-3.
20. Shankar EM, Vignesh R, Murugavel KG, et al. Immune reconstitution inflammatory syndrome in association with HIV/AIDS and tuberculosis: Views over hidden possibilities. AIDS Res Ther 2007; 4:29. This paper presents a challenging view on the possible role of LPS in tuberculosis IRD.
21. Appelberg R. Pathogenesis of Mycobacterium avium infection: typical responses to an atypical mycobacterium? Immunol Res 2006; 35:179-190.
22. Riddell J, Kaul DR, Karakousis PC, et al. Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes. J Transl Med 2007; 5:50.
23. Ustianowski AP, Lawn SD, Lockwood DN. Interactions between HIV infection and leprosy: a paradox. Lancet Infect Dis 2006; 6:350-360.
24. Bell HC, Heath CH, French MA. Pulmonary Mycobacterium celatum immune restoration disease: immunopathology and response to corticosteroid therapy. AIDS 2005; 19:2047-2049.
25. Lehloenya R, Meintjes G. Dermatologic manifestations of the immune reconstitution inflammatory syndrome. Dermatol Clin 2006; 24:549-570; vii.
26. Stone SF, Price P, Brochier J, French MA. Plasma bioavailable interleukin-6 is elevated in human immunodeficiency virus-infected patients who experience herpesvirus-associated immune restoration disease after start of highly active antiretroviral therapy. J Infect Dis 2001; 184:1073-1077.
27. Domingo P, Torres OH, Ris J, Vazquez G. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med 2001; 110:605-609.
28. Feller L, Wood NH, Lemmer J. Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007; 104:455-460.
29. - T lymphocytes from HIV-1-infected patients secrete factors that induce endothelial cell proliferation and acquisition of Kaposi's sarcoma cell features. J Interferon Cytokine Res 2003; 23:523-531.
30. Connick E, Kane MA, White IE, et al. Immune reconstitution inflammatory syndrome associated with Kaposi sarcoma during potent antiretroviral therapy. Clin Infect Dis 2004; 39:1852-1855.
31. Lambert M, Gannage M, Karras A, et al. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood 2006; 108:3871-3880.
32. Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005; 19:635-644.
33. Stone SF, Price P, French MA. Cytomegalovirus (CMV)-specific CD8+ T cells in individuals with HIV infection: correlation with protection from CMV disease. J Antimicrob Chemother 2006; 57:585-588.
34. Stone SF, Price P, Tay-Kearney ML, French MA. Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. J Infect Dis 2002; 185:1813-1817.
35. Bronke C, Palmer NM, Jansen CA, et al. Dynamics of cytomegalovirus (CMV)-specific T cells in HIV-1-infected individuals progressing to AIDS with CMV end-organ disease. J Infect Dis 2005; 191:873-880.
36. Price P, Witt C, de Santis D, French MA. Killer immunoglobulin-like receptor genotype may distinguish immunodeficient HIV-infected patients resistant to immune restoration diseases associated with herpes virus infections. J Acquir Immune Defic Syndr 2007; 45:359-361.
37. Aandahl EM, Michaelsson J, Moretto WJ, et al. Human CD4+ CD25+ regulatory T cells control T-cell responses to human immunodeficiency virus and cytomegalovirus antigens. J Virol 2004; 78:2454-2459.
38. Tsai SL. Immunopathogenesis of viral hepatitis B and C. Changgeng Yi Xue Za Zhi 1999; 22:159-170.
39. John M, Flexman J, French MA. Hepatitis C virus-associated hepatitis following treatment of HIV-infected patients with HIV protease inhibitors: an immune restoration disease? AIDS 1998; 12:2289-2293.
40. Koralnik IJ. New insights into progressive multifocal leukoencephalopathy. Curr Opin Neurol 2004; 17:365-370.
41. Vendrely A, Bienvenu B, Gasnault J, et al. Fulminant inflammatory leukoencephalopathy associated with HAART-induced immune restoration in AIDS-related progressive multifocal leukoencephalopathy. Acta Neuropathol (Berl) 2005; 109:449-455.
42. Safdar A, Rubocki RJ, Horvath JA, et al. Fatal immune restoration disease in human immunodeficiency virus type 1-infected patients with progressive multifocal leukoencephalopathy: impact of antiretroviral therapy-associated immune reconstitution. Clin Infect Dis 2002; 35:1250-1257.
43. Gray F, Bazille C, dle-Biassette H, et al. Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol 2005; 11 (Suppl 3):16-22.
44. Zheng CF,Ma LL, JonesGJ, et al. Cytotoxic CD4+ T cells use granulysin to kill Cryptococcus neoformans, and activation of this pathway is defective in HIV patients. Blood 2007; 109:2049-2057.
45. Lawn SD, Bekker LG, Myer L, et al. Cryptococcocal immune reconstitution disease: a major cause of early mortality in a South African antiretroviral programme. AIDS 2005; 19:2050-2052.
46. Shelburne SA III, Darcourt J, White AC Jr, et al. The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy. Clin Infect Dis 2005; 40:1049-1052.
47. Wright TW, Gigliotti F, Finkelstein JN, et al. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999; 104:1307-1317.
48. Bhagwat SP, Gigliotti F, Xu H, Wright TW. Contribution of T cell subsets to the pathophysiology of Pneumocystis-related immunorestitution disease. Am J Physiol Lung Cell Mol Physiol 2006; 291:L1256-L1266.
49. Lawn SD, Wilkinson RJ. Immune reconstitution disease associated with parasitic infections following antiretroviral treatment. Parasite Immunol 2006; 28:625-633.
50. Lawn SD. Immune reconstitution disease associated with parasitic infections following initiation of antiretroviral therapy. Curr Opin Infect Dis 2007; 20: 482-488.
51. Lawn SD. Schistosomiasis and immune reconstitution disease. AIDS 2007; 21:1986-1987.
52. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005; 5:361-373.
53. + lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest 1999; 103:1391-1398.
54. Saunders BM, Britton WJ. Life and death in the granuloma: immunopathology of tuberculosis. Immunol Cell Biol 2007; 85:103-111.
55. Morizane S, Suzuki D, Tsuji K, et al. The role of CD4 and CD8 cytotoxic T lymphocytes in the formation of viral vesicles. Br J Dermatol 2005; 153: 981-986.
56. Swain SD, Meissner NN, Harmsen AG. CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in pneumocystis pneumonia in B-cell-deficient mice. Am J Pathol 2006; 168:466-475.
57. Wilson MS, Mentink-Kane MM, Pesce JT, et al. Immunopathology of schistosomiasis. Immunol Cell Biol 2007; 85:148-154.
58. Mwanakasale V, Vounatsou P, Sukwa TY, et al. Interactions between Schistosoma haematobium and human immunodeficiency virus type 1: the effects of coinfection on treatment outcomes in rural Zambia. Am J Trop Med Hyg 2003; 69:420-428.
59. Pearce EJ. Priming of the immune response by schistosome eggs. Parasite Immunol 2005; 27:265-270.
60. Hardwick C, White D, Morris E, et al. Montelukast in the treatment of HIV associated immune reconstitution disease. Sex Transm Infect 2006; 82: 513-514.
61. Lipman MC, Carding SK. Successful drug treatment of immune reconstitution disease with the leukotriene receptor antagonist, montelukast: a clue to pathogenesis? AIDS 2007; 21:383-384.
62. Robertson J, Meier M, Wall J, et al. Immune reconstitution syndrome in HIV: validating a case definition and identifying clinical predictors in persons initiating antiretroviral therapy. Clin Infect Dis 2006; 42:1639-1646.